Mechanism of PD1 on cardiac inflammation resolution during heart failure development
PD1 在心力衰竭发展过程中解决心脏炎症的机制
基本信息
- 批准号:10345497
- 负责人:
- 金额:$ 57.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAttenuatedBar CodesBioinformaticsBlocking AntibodiesCD8-Positive T-LymphocytesCardiacCardiotoxicityCardiovascular DiseasesCardiovascular systemCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCessation of lifeDevelopmentFailureGenesGenomicsHeart failureIL17 geneIL1R1 geneImmuneImmune responseInfiltrationInflammationInterleukin-17InvestigationKnockout MiceLabelLeftLungMediatingMembrane ProteinsMetabolic PathwayMusMyocarditisPathway interactionsPatientsPlayProductionProteinsPulmonary HypertensionPulmonary InflammationResolutionRoleSignal TransductionStressT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTestingToxic effectTumor-infiltrating immune cellsVascular Endothelial Celladaptive immune responsebasecancer therapyconstrictioncytokine release syndromeexperimental studyheart cellinnovationinterestmacrophageprogrammed cell death protein 1pulmonary functionright ventricular failuresham surgerytargeted cancer therapy
项目摘要
Cardiovascular inflammation promotes Heart failure (HF) development. However, mechanism of cardiac
inflammation resolution during HF development is still poorly understood. Programmed cell death protein 1 (PD1)
is a protein that keeps the body’s immune responses in check, both by inhibiting initial T cell induction and by
maintaining T cell tolerance. PD1 blocking antibodies are used in cancer treatment, but the treatment also leads
to cardiac toxicity in some patients. We found that PD1 KO or PD1 blocking antibodies dramatically exacerbated
transverse aortic constriction (TAC)-induced cardiac inflammation, HF, and death, indicating PD1 exerts a more
important role under stress conditions. To understand mechanisms of PD1 inhibition in cardiac inflammation, we
studied cardiac immune cells and vascular endothelial cells from wild type and PD1 KO mice after sham or TAC
by using single-cell CITE-seq together with barcoded antibodies for membrane protein labeling. Using single-cell
CITE-seq, we also studied lung immune cells from HF mice and sham mice. Bioinformatics analyses have
provided enormously information of these cells – showing dramatic alterations of cell clusters, enriched pathways
of innate & adaptive immune responses, and changes of metabolic pathways in various immune cell subsets in
HF mice, or in PD1 KO after TAC. gdT cells (a subset of T cells) can be divided into either IL-17 (gdT17) or IFNg
producers. CITE-seq of lung immune cells showed that HF caused dramatic changes of various T cell and
macrophage clusters, a dramatic increase of PD1 in Th17 and gdT17 cells, suggesting PD1 exerts an important
role in suppressing Th17, and gdT17 cells as well as HF progression. CITE-seq in cardiac immune cells showed
that infiltration of CD8+ T cells and gdT cells increased in PD1 KO mice after TAC, and these infiltrated cells are
IFNg+ cells, indicating that CD8+ T cells, gdT cells, and IFNg may contribute to the exacerbated cardiac
inflammation in PD1 KO mice. Based on these exciting findings, we hypothesize that TAC-induced cardiac and
pulmonary inflammation resolution is regulated by PD1 through both conserved and unique pathways at least
partially controlled by IFNg and IL17 produced by CD8+ T cells, gdT cells, and Th17, respectively. To enhance
the innovative rigor of our investigation of the role of PD1 in cardiac inflammation and HF, we will also study CD8
cell specific PD1 KO mice. Aim-1. Test the hypothesis that IFNg and CD8+ T cells contribute to the exacerbated
cardiac inflammation, cytokine storm, and HF in PD1 KO after TAC. In additon, we will determine whether PD1
KO in CD8+ T cells is sufficient to exacerbate TAC-induced cardiac inflammation and HF. Aim-2. Determine the
roles and underlying mechanisms of IL17 and gdT cells in promoting TAC-induced cardiac inflammation and HF
after PD1 inhibition. This application is highly responsive to the Notice of Special Interest NOT-ES-20-018 as the
proposed studies will advance our understanding of the mechanisms of PD1 and T cells in cardiac and lung
inflammation resolution, and the conserved & unique changes in cardiac and lung immune cell clusters during
HF development and progression.
心血管炎症促进心力衰竭(HF)的发展。然而,心脏的作用机制
心力衰竭发展过程中的炎症消退仍然知之甚少。程序性细胞死亡蛋白1(PD1)
是一种蛋白质,通过抑制最初的T细胞诱导和通过
维持T细胞耐受性。PD1阻断抗体用于癌症治疗,但治疗也导致
对某些患者的心脏毒性有影响。我们发现PD1KO或PD1封闭抗体显著加剧
横断性主动脉缩窄(TAC)引起的心脏炎症、心衰和死亡,表明PD1发挥了更多的
在压力条件下发挥重要作用。为了了解PD1抑制心脏炎症的机制,我们
假手术和TAC对野生型和PD1KO小鼠心脏免疫细胞和血管内皮细胞的影响
用单细胞CITE-SEQ结合条形码抗体进行膜蛋白标记。使用单电池
Cite-Seq,我们还研究了HF小鼠和假手术小鼠的肺免疫细胞。生物信息学分析已经
提供了这些细胞的大量信息-显示了细胞团的戏剧性变化,丰富了途径
先天免疫反应和获得性免疫反应及免疫细胞亚群代谢途径的变化
心衰小鼠,或TAC后PD1KO。GDT细胞(T细胞的一个亚群)可分为IL-17(GdT17)或IFNG
制片人。肺免疫细胞CITE-SEQ结果显示,HF可引起多种T细胞和T细胞的显著变化
巨噬细胞簇,在Th17和gdT17细胞中PD1的表达急剧增加,提示PD1在
在抑制Th17和gdT17细胞以及HF进展中的作用。心脏免疫细胞中的CITE-SEQ显示
PD1KO小鼠TAC后CD8+T细胞和GDT细胞的浸润增加,这些浸润的细胞
IFNG+细胞,提示CD8+T细胞、GDT细胞和IFNG可能参与了心脏疾病的加重。
PD1KO小鼠的炎症反应。基于这些令人兴奋的发现,我们假设TAC诱导的心脏和
PD1至少通过保守和独特的途径调节肺部炎症的消退
分别由CD8+T细胞、GDT细胞和Th17细胞产生的IFNG和IL17部分调控。为了增强
我们对PD1在心脏炎症和心力衰竭中的作用的研究具有创新的严谨性,我们还将研究CD8
细胞特异性PD1KO小鼠。AIM-1。验证IFNG和CD8+T细胞参与急性加重期的假设
TAC后PD1KO的心脏炎症、细胞因子风暴和心力衰竭。此外,我们将确定PD1是否
CD8+T细胞中的KO足以加重TAC诱导的心脏炎症和心衰。AIM-2。确定
IL-17和GDT细胞在TAC诱导的心脏炎症和心衰中的作用及其机制
PD1抑制后。本申请高度响应特别关注通知NOT-ES-20-018作为
拟议的研究将促进我们对PD1和T细胞在心脏和肺中的作用机制的理解
炎症消退与心肺免疫细胞团保守而独特的变化
心衰的发展和进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YINGJIE CHEN其他文献
YINGJIE CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YINGJIE CHEN', 18)}}的其他基金
Mechanism of PD1 on cardiac inflammation resolution during heart failure development
PD1 在心力衰竭发展过程中解决心脏炎症的机制
- 批准号:
10557113 - 财政年份:2022
- 资助金额:
$ 57.47万 - 项目类别:
Mechanisms of Treg and IL-35 in Regulating LV Failure-induced Lung Remodeling and Right Heart Hypertrophy
Treg 和 IL-35 调节左室衰竭所致肺重塑和右心肥厚的机制
- 批准号:
10199004 - 财政年份:2018
- 资助金额:
$ 57.47万 - 项目类别:
Mechanisms of Treg and IL-35 in Regulating LV Failure-induced Lung Remodeling and Right Heart Hypertrophy
Treg 和 IL-35 调节左室衰竭所致肺重塑和右心肥厚的机制
- 批准号:
10116063 - 财政年份:2018
- 资助金额:
$ 57.47万 - 项目类别:
Molecular mechanism of 4E-binding proteins on heart failure development
4E结合蛋白对心力衰竭发展的分子机制
- 批准号:
8461159 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
Regulation of the novel mTOR suppressor DDIT4 in the failing heart
新型 mTOR 抑制剂 DDIT4 在衰竭心脏中的调节
- 批准号:
8113127 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
Molecular mechanism of 4E-binding proteins on heart failure development
4E结合蛋白对心力衰竭发展的分子机制
- 批准号:
8666798 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
Molecular mechanism of 4E-binding proteins on heart failure development
4E结合蛋白对心力衰竭发展的分子机制
- 批准号:
8183136 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
Regulation of the novel mTOR suppressor DDIT4 in the failing heart
新型 mTOR 抑制剂 DDIT4 在衰竭心脏中的调节
- 批准号:
8244427 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
Molecular mechanism of 4E-binding proteins on heart failure development
4E结合蛋白对心力衰竭发展的分子机制
- 批准号:
8311646 - 财政年份:2011
- 资助金额:
$ 57.47万 - 项目类别:
DDAH1 effects on endogenous NOS inhibitors and vascular endothelial function
DDAH1 对内源性 NOS 抑制剂和血管内皮功能的影响
- 批准号:
8111967 - 财政年份:2010
- 资助金额:
$ 57.47万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 57.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 57.47万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 57.47万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 57.47万 - 项目类别:
Idea to Innovation